Grifols A : Our rating under review following Gotham’s report
>Gotham City Research has just issued a report on Grifols - The report says that the company has manipulated its reported debt and EBITDA to artificially reduce its leverage which it believes is closer to 10x-13x net debt/EBIDTA. While the report flags some known facts there a number of issues related to the relationship between Grifols and Scranton (Grifols family vehicle) that we would like to study and discuss with the company as this could alter our investment ca...Grifols is engaged in developing, manufacturing and distributing a range of plasma derivative products. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend the lives of individuals who suffer from chronic and acute conditions. Co. also specializes in providing infusion solutions, nutrition products, medical devices, diagnostic instrumentation and reagents for use in hospitals and clinics. Co.'s products and services are used by healthcare providers in approximately 100 countries. Co.'s business is organized into three divisions: Bioscience, Diagnostic, Hospital and Raw Materials.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.